Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD-IO: Ipilimumab, SBRT, and Cemiplimab in Advanced NSCLC
NCT05401786Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2023
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Started Jan 2023; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05401786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05401786.